Fig. 4: Cumulative incidence rates of outcomes stratified by low-risk frailty group and high-risk frailty group.
From: Metabolomic characterization of frailty identifies subtype-specific management strategies
The Kaplan–Meier survival curve was employed to estimate the cumulative density of events at specific time points. The Log-rank test was used to evaluate statistical differences between survival curves. a Coronary artery disease. b Heart failure. c MACE. d MI. e Type 2 diabetes. f MASLD g COPD. h SLD. i PAD. j ESRD. k Kidney cancer. l Lung Cancer. m AAA. n All-cause mortality. Significance level: P < 0.05. MACE major adverse cardiovascular events, MI myocardial infarction, MASLD metabolic dysfunction-associated steatotic liver disease, COPD chronic obstructive pulmonary disease, SLD severe liver disease, PAD peripheral artery disease, ESRD end-stage renal disease, AAA abdominal aortic aneurysm.
